A Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors (ACTRN12625000268448)

A study is testing a new diagnostic product, to detect tumour tissue throughout the body using a radioactive substance a positron emission tomography (PET) tracer, that targets a protein Gastrin-Releasing Peptide Receptor (GRPR) which is found in various cancer types. This is not a treatment study. No treatment will be provided to you as part of this study. This study is testing a new imaging product only.

Trial phase

Phase 1

Trial participation type

This trial is for clinical research of something other than a drug or device.

Principal investigator

Dr David Nadebaum

Key inclusion data

Inclusions: Adults (18+) with advanced metastatic breast, prostate, lung (MSCLC/SCLC) or colorectal cancer; Stable brain metastases allowed if treated at least 4 weeks prior and symptoms are controlled; Must have measurable disease and be able to provide informed consent. Exclusions: Any medical condition that would, in the Investigators judgment, prevent the participants full participation in the clinical study due to safety concerns or compliance with clinical study procedures; Recent serious wounds, surgeries or uncontrolled side effects from prior cancer treatment.